Literature DB >> 31611047

A Metabolic Brain Pattern Associated With Anti-N-Methyl-D-Aspartate Receptor Encephalitis.

Nora Kerik-Rotenberg1, Ivan Diaz-Meneses2, Rodrigo Hernandez-Ramirez2, Rodrigo Muñoz-Casillas2, Carlos A Reynoso-Mejia2, Jose Flores-Rivera3, Mariana Espinola-Nadurille4, Jesus Ramirez-Bermudez4, Carlos Aguilar-Palomeque2.   

Abstract

BACKGROUND: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis causes substantial neurological disability. Autoantibodies causing encephalitis directed against the neuronal cell surface or synapse are of diagnostic importance giving the possibility of successful immunotherapy.
OBJECTIVE: In this study, we aim to provide supporting evidence that brain 18F-FDG-PET may be helpful in identifying likely patterns of regional brain glucose metabolism.
METHODS: Thirty-three patients (18 men and 15 women; age range of 17-55 y) with positive NMDA receptor antibody encephalitis that underwent an 18F-FDG-PET imaging examination were prospectively selected and compared with a reference group of 14 brain 18F-FDG-PET scans from healthy volunteers using voxel-based statistical analysis. Clusters of hyper- and hypo-metabolism were reported for the whole sample of patients (FWE-corrected P < 0.05), and uncorrected at P < 0.005 for a group of relapsed patients.
RESULTS: Mixed metabolic patterns (focal/bilateral hypermetabolism in the temporal lobe, insula, and cerebellum; associated with severe bilateral hypometabolism in the occipital and parietal lobes) were found.
CONCLUSIONS: Our findings suggest that 18F-FDG-PET should be included as an imaging tool when assessing affected patients in the clinical workup to rule out anti-NMDA encephalitis and help determine the most effective treatment.
Copyright © 2019 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FDG; acute disorder; encephalitis; neuropsychiatry; positron emission tomography

Mesh:

Substances:

Year:  2019        PMID: 31611047     DOI: 10.1016/j.psym.2019.08.007

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  6 in total

Review 1.  Autoantibody Encephalitis: Presentation, Diagnosis, and Management.

Authors:  Eric Lancaster
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

Review 2.  [18F]FDG brain PET and clinical symptoms in different autoantibodies of autoimmune encephalitis: a systematic review.

Authors:  Fardin Nabizadeh; Elham Ramezannezhad; Alireza Sardaripour; Seyed Ali Seyedi; Negin Salehi; Nasim Rezaeimanesh; Abdorreza Naser Moghadasi
Journal:  Neurol Sci       Date:  2022-04-29       Impact factor: 3.830

Review 3.  Autoimmune Encephalitis in Latin America: A Critical Review.

Authors:  Gabriel de Albuquerque Vasconcelos; Rodrigo Montenegro Barreira; Karmelita Emanuelle Nogueira Torres Antoniollo; Alina Maria Nuñez Pinheiro; Cíntia Fernandes Rodrigues Maia; Danyela Martins Bezerra Soares Alves; Paulo Ribeiro Nóbrega; Pedro Braga-Neto
Journal:  Front Neurol       Date:  2021-01-21       Impact factor: 4.003

4.  Distinct cerebral 18F-FDG PET metabolic patterns in anti-N-methyl-D-aspartate receptor encephalitis patients with different trigger factors.

Authors:  Jingjie Ge; Bo Deng; Yihui Guan; Weiqi Bao; Ping Wu; Xiangjun Chen; Chuantao Zuo
Journal:  Ther Adv Neurol Disord       Date:  2021-02-24       Impact factor: 6.570

5.  Cerebral gray matter volume changes in patients with anti-N-methyl-D-aspartate receptor encephalitis: A voxel-based morphometry study.

Authors:  Qijia Long; Zongxia Lv; Jingyuan Zhao; Ke Shi; Chunyan Li; Binglin Fan; Jinou Zheng
Journal:  Front Neurol       Date:  2022-07-25       Impact factor: 4.086

Review 6.  Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis.

Authors:  Manon Bordonne; Mohammad B Chawki; Matthieu Doyen; Aurelie Kas; Eric Guedj; Louise Tyvaert; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-07       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.